Unmet Need
The need for multifactorial therapies
Retinal vascular diseases are a leading cause of vision loss worldwide. Age-related macular degeneration (AMD) alone affects nearly 200 million people, with 10 million experiencing moderate to severe vision loss.1 The neovascular form of AMD (nAMD) accounts for approximately 90% of this vision loss.2
Multiple angiogenic pathways contribute to retinal vascular disease. The best treatment options to date are repeated injections of anti-angiogenic drugs which do not block VEGF-R2 and Tie-2 receptors simultaneously.
When only the VEGF-A pathway is treated, both VEGF-C and Ang-2 can become more active in retinal vascular diseases (leading to suboptimal efficacy) or become refractory (requiring more frequent treatment).3
Only ~30% of patients have a form of nAMD that responds optimally to VEGF-A monotherapy.5-7 Therefore, most patients with nAMD might benefit from a treatment that could simultaneously target pan-VEGF and Ang-2.
RO-104
RO-104 targets multiple dominant angiogenic pathways in retinal disease
Developed using our proprietary RevMod Platform, RO-104 is the first candidate to provide pan-VEGF blockade while also inhibiting Ang-2.
As a first-in-class, fully human TriMod biologic, RO-104:
- Binds 3 targets simultaneously with matched, high affinity
- Binds and inhibits multiple VEGF family and Ang-2 proteins
- Demonstrates intended efficacy in established animal models compared to approved anti-VEGF therapeutics such as Eylea® and Vabysmo®
Pipeline
A pipeline of discovery and development
Leveraging our proprietary RevMod Platform, RevOpsis is committed to developing a robust pipeline of therapeutic candidates to target prevalent chronic multifactorial ophthalmic diseases, including:
- neovascular age-related macular degeneration (nAMD)
- diabetic macular edema (DME)
- retinal vein occlusion (RVO)
- dry AMD
- uveitic macular edema
- thyroid eye disease.
The RevMod Platform can also be applied across therapeutic categories, including diseases of the immune system, autoimmune diseases, and oncology. We are poised to address unmet needs in millions of patients worldwide.
